NCT02648724: Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: MET
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have MET gene amplification
Exclusions: Untreated central nervous system (CNS) or leptomeningeal metastases

Comments are closed.

Up ↑